Get the Daily Brief
Latest Biotech News
Shingles shot linked to lower dementia risk: observational analysis
A study published in Nature Communications reports an association between receipt of the recombinant zoster vaccine (RZV) and reduced risk of developing dementia. Researchers analyzed population...
Engineered immune cells cut toxic brain proteins: preclinical advance
Researchers at Washington University School of Medicine and the Weizmann Institute reported engineered immune cells that target and reduce toxic brain proteins linked to neurodegeneration. Using...
Histone lactylation fuels immune escape in pancreatic cancer
A Nature Communications paper from Zhang, Ma, Wan and colleagues identifies histone lactylation as an epigenetic driver of immune evasion in pancreatic ductal adenocarcinoma. The work shows...
IRB Barcelona opens Spain’s first spatial omics platform — national scale hub
IRB Barcelona launched Spain’s first fully integrated Spatial Omics Platform to provide high‑throughput spatial transcriptomics and proteomics for biomedical research. The platform consolidates...
Lilly buys Orna for $2.4B — stakes a claim in in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to secure an in vivo CAR‑T platform and accelerate entry into genetic medicine. Orna’s circular RNA plus lipid nanoparticle...
FDA rejects Regenxbio gene therapy — Hunter syndrome bid denied
The U.S. Food and Drug Administration issued a complete response letter rejecting Regenxbio’s RGX‑121 for mucopolysaccharidosis type II (Hunter syndrome). The agency flagged concerns about trial...
Novo Nordisk sues Hims — FDA warns against copycat Wegovy pills
Novo Nordisk filed patent litigation against telehealth firm Hims & Hers over an allegedly infringing semaglutide pill and is seeking substantial damages. The complaint centers on Hims’ pill...
Takeda taps Iambic — another pharma AI drug‑discovery tie‑up
Takeda signed a multiyear R&D collaboration with AI firm Iambic to accelerate small‑molecule discovery across oncology, gastrointestinal and inflammation targets. The deal reflects Takeda’s...
AI agents move into trials — sites get decision‑support tools
Medable launched an Agentic AI designed to assist principal investigators in reviewing and reconciling electronic clinical outcome assessment data, shifting routine reconciliation tasks toward...
FDA revises Yescarta label — opens CD19 CAR‑T to primary CNS lymphoma
The FDA approved a label update for axicabtagene ciloleucel (Yescarta), removing a prior contraindication for treating patients with primary CNS lymphoma. Dana‑Farber investigators contributed...
First‑in‑human immune cell therapy shows responses in advanced lymphoma
Researchers at The University of Texas MD Anderson Cancer Center reported first‑in‑human data for RB‑1355, an engineered immune‑cell therapy tested in relapsed or refractory non‑Hodgkin lymphoma....
Pre‑op chemotherapy improves survival in early‑stage pancreatic cancer — Mayo study
A Mayo Clinic multicenter analysis of more than 1,400 patients found that administering chemotherapy before surgery significantly improved survival for early‑stage pancreatic cancer compared with...
Shingles vaccine associated with lower dementia risk — observational finding
A study published in Nature Communications reported an association between receipt of the recombinant zoster vaccine (RZV) and a reduced risk of developing dementia. The authors used large...
Faster RNA synthesis and cleaner sequencing — new tools to speed RNA therapeutics
UC Irvine scientists reported a novel enzyme that accelerates rapid and precise RNA synthesis, addressing a bottleneck for mRNA therapeutics and diagnostics. In parallel, a deep‑learning tool...
Lilly to buy Orna Therapeutics — in vivo CAR-T push
Eli Lilly announced an acquisition of Orna Therapeutics for up to $2.4 billion to gain access to Orna’s circular RNA platform and clinical-ready in vivo CAR-T candidate ORN-252. The deal brings...
FDA rejects Regenxbio gene therapy: Hunter syndrome bid denied
The Food and Drug Administration issued a complete response and rejected Regenxbio’s accelerated approval application for RGX-121, a one-time gene therapy for the severe form of Hunter syndrome....
Novo Nordisk sues Hims... Wegovy pill dispute heats up
Novo Nordisk filed a patent infringement suit against Hims & Hers over a compounded semaglutide pill that the telehealth company began marketing as a low-cost alternative to Wegovy. Novo alleges...
Medable launches Agentic AI — trial oversight enters the machine age
Medable introduced an ‘Agentic AI’ product designed to assist principal investigators in assessing electronic clinical outcome assessment data and reducing manual reconciliation. The platform...
Takeda signs multiyear AI deal with Iambic — small‑molecule focus
Takeda entered a multiyear partnership with AI drug discovery company Iambic to accelerate small-molecule programs across oncology, gastrointestinal, and inflammatory targets. The collaboration...
Engineered immune cells target and reduce toxic brain proteins
Researchers at Washington University School of Medicine and the Weizmann Institute deployed engineered immune cells—using CAR‑T concepts—to clear toxic protein aggregates in Alzheimer’s disease...